FOLH1 and prostate cancer: In parallel, several PSMA-based radioimmunotherapeutics and anti-PSMA antibodies complexed with small molecule inhibitors or chemotherapeutics have completed advanced clinical phase testing and hold promise for improved management of prostatic cancer in men [26, 27].